The estimated Net Worth of Ron Bentsur is at least $1.65 Million dollars as of 20 March 2023. Mr. Bentsur owns over 2,300 units of Beyond Air stock worth over $55,998 and over the last 11 years he sold XAIR stock worth over $1,509,240. In addition, he makes $83,730 as Independent Director at Beyond Air.
Sign up
Mr. Bentsur XAIR stock SEC Form 4 insiders trading
Ron has made over 24 trades of the Beyond Air stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 2,300 units of XAIR stock worth $14,904 on 20 March 2023.
The largest trade he's ever made was exercising 50,000 units of Beyond Air stock on 22 November 2021 worth over $183,000. On average, Ron trades about 8,243 units every 84 days since 2013. As of 20 March 2023 he still owns at least 144,736 units of Beyond Air stock.
You can see the complete history of Mr. Bentsur stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ron Bentsur biography
Ron E. Bentsur serves as Independent Director of the Company. Mr. Bentsur has served as Chief Executive Officer and Director of UroGen Pharma, Ltd. since August 2015. From 2009 through April 2015, Mr. Bentsur served as Chief Executive Officer and Director of Keryx Biopharmaceuticals, Inc. Mr. Bentsur’s tenure as CEO of Keryx Biopharmaceuticals culminated in the September 2014 FDA approval of Auryxia TM (ferric citrate) and its December 2014 U.S. launch. Prior to joining Keryx Biopharmaceuticals, Inc., from 2006 to 2009, Mr. Bentsur served as Chief Executive Officer of XTL Biopharmaceuticals, Ltd. Prior to that, Mr. Bentsur served as Vice President Finance and Chief Financial Officer of Keryx Biopharmaceuticals, Inc., as Director of Technology Investment Banking at Leumi Underwriters, where he was responsible for all technology and biotechnology private placement and advisory transactions, and as a New York City-based investment banker, primarily at ING Barings Furman Selz. Mr. Bentsur holds a B.A. in Economics and Business Administration with distinction from the Hebrew University of Jerusalem and an M.B.A., magna cum laude, from New York University’s Stern Graduate School of Business. Mr. Bentsur also serves as Director of Stemline Therapeutics, Inc. Ron’s vast industry experience is invaluable to our Board.
What is the salary of Ron Bentsur?
As the Independent Director of Beyond Air, the total compensation of Ron Bentsur at Beyond Air is $83,730. There are 11 executives at Beyond Air getting paid more, with Steven Lisi having the highest compensation of $2,969,660.
How old is Ron Bentsur?
Ron Bentsur is 54, he's been the Independent Director of Beyond Air since 2017. There are 5 older and 7 younger executives at Beyond Air. The oldest executive at Beyond Air, Inc. is Michael A. Gaul, 65, who is the Sr. VP of Operations.
What's Ron Bentsur's mailing address?
Ron's mailing address filed with the SEC is C/O BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY, NY, 11530.
Insiders trading at Beyond Air
Over the last 5 years, insiders at Beyond Air have traded over $4,582,444 worth of Beyond Air stock and bought 3,519,117 units worth $12,396,434 . The most active insiders traders include Robert Carey, Steven A. Lisi, and Amir Avniel. On average, Beyond Air executives and independent directors trade stock every 17 days with the average trade being worth of $15,492. The most recent stock trade was executed by Steven A. Lisi on 15 August 2024, trading 50,000 units of XAIR stock currently worth $18,500.
What does Beyond Air do?
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of persistent pulmonary hypertension of the newborn; acute viral pneumonia, including COVID-19; bronchiolitis and nontuberculous mycobacteria lung infections; and solid tumors. It operates in Israel, Ireland, Australia, and the European Union. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
What does Beyond Air's logo look like?
Complete history of Mr. Bentsur stock trades at Stemline Therapeutics and Beyond Air
Beyond Air executives and stock owners
Beyond Air executives and other stock owners filed with the SEC include:
-
Steven Lisi,
Chairman of the Board, Chief Executive Officer -
Amir Avniel,
President, Chief Operating Officer, Director -
Adam Newman,
Chief Legal Officer and General Counsel -
Steven Adam Lisi,
CEO & Chairman -
Duncan Fatkin,
Chief Commercial Officer -
Douglas Beck,
Chief Financial Officer -
Amir Avniel,
Co-Founder, Pres, COO & Director -
Douglas J. Beck CPA, CPA,
Consultant -
William Forbes,
Independent Director -
Erick Lucera,
Independent Director -
Robert Carey,
Independent Director -
Yoori Lee,
Independent Director -
Ron Bentsur,
Independent Director -
Bob Yedid,
IR Contact Officer -
Prof. Andrew R. Colin M.D.,
Chief Medical Officer & Member of Scientific Advisory Board -
Kori-Ann Taylor,
Head of Marketing -
Rebecca Van Doren,
Head of Sales -
Maria Yonkoski,
Head of Investor Relations -
Douglas Quinton Larson,
CFO, Principal Financial Officer & Principal Accounting Officer -
Hila Confino Ph.D.,
Research Project Mang. -
Michael A. Gaul,
Sr. VP of Operations -
Ali Ardakani,
Sr. VP of Device & Bus. Devel. -
Dr. Giora Davidai M.D.,
Chief Medical Officer -
Douglas Quinton Larson,
Chief Financial Officer -
Michael A. Gaul,
Chief Operating Officer -
Jeff Lynn Myers,
Chief Medical Officer